The Driving Force Behind New Drug Discovery

Partnership with TB Alliance for anti-tuberculosis drug discovery from natural products

November 19, 2021

Isshin Tanaka

Applied Microbiology Group Biological Research Department



My working experience in drug discovery from natural products



1995–2007

Sankyo Co., Ltd.

2007–2011 Daiichi Sankyo Co., Ltd.


Developed and commercialized natural product-derived pravastatin as a cholesterol-lowering drug

2011 to present Daiichi Sankyo RD Novare Co., Ltd.

My initial task:

Curating a microorganism library

Basidiomycetes that form minute basidiocarp



My current task:


- Finding an effective use of the microorganism library and microbial extract libraries
- Developing new technologies for drug discovery from natural products



What is Daiichi Sankyo RD Novare?




Daiichi Sankyo RD Novare was established in 2011 with a mission of playing a role in the global R&D function of the Daiichi Sankyo Group by building an advanced technological foundation that supports innovative drug discovery and a high-quality clinical development process





Microorganism library of Daiichi Sankyo RD Novare





- Contains a large number of strains isolated from terrestrial and marine environments in Japan
- Organized by molecular systematics based on rDNA
- Utilizing the crude fermentation extracts derived from the microorganism library in our research
- This library and research function were inherited by Daiichi Sankyo RD Novare from Sankyo

5

The origin of our collaboration with TB Alliance in 2014

- TB Alliance planned to conduct anti-tuberculosis drug discovery research from natural products in Japan and had been surveying Japanese research institutes through the GHIT Fund
- Daiichi Sankyo RD Novare was seeking a chance to expand utilization of microorganism library




We received an explanation from the GHIT Fund and understood the significance of collaboration

- Strong needs for Novare's microorganism library
- Supported research costs by GHIT Fund and PDPs
- Expected contribution to global health through our expertise in drug discovery research

Screening project started in 2015






- molecular systematics
- Use Mycobacterium tuberculosis, not Mycobacterium smegmatis, for phenotype screening




Status of GHIT-sponsored projects with TB Alliance



Roles in the screening project





Role of Daiichi Sankyo RD Novare in the Hit-to-Lead project



- > Make the derivatization plan with TB Alliance
- Provide the parent or analog compounds used for derivatization
 - Gram-scale compounds are needed
 - Analogous compounds or basic skeletons of the compounds useful for diversification of semi-synthesis




To provide the compounds efficiently, we wanted to utilize genomic information and biosynthetic genes of the producing microorganisms



Prospects for utilization of microbial genome







- 1. Microorganism libraries are still an attractive source of new drug leads where new active compounds can be found
- 2. With support from GHIT Fund, this proven and limitless source can be put to great use for neglected diseases
- 3. A combination of the know-how accumulated within our organization and new approaches in microbial genomes and biosynthetic genes can generate novel leads



Acknowledgements

Daiichi-Sankyo

OAIICHI SANKYO RD NOVARE CO., LTD.

Biological Research Department

Yasunori Muramatsu

Youko Fujita

Tadaaki Morishita

Masaaki Kizuka

Takahiro Miyauchi

Yasunori Ono

Emi Kurosawa

Shinobu Abe

Tomio Ishikawa

Hanako Nishizawa

Organic & Biomolecular Chemistry Department

Marumoto Shinji Hiroki Shimizu Tetsunori Fujisawa

Hiroshi Maruoka

Pharmaceutical & ADMET Research Department

Yoshimine Fujii

Masaru Iwasaki



GHIT Fund Management teams

TB ALLIANCE 🔂 TB Alliance

Dr. Takushi Kaneko Dr. Nader Fotouhi Zaid Tanvir

<Cross-sector partnerships of TB ALLIANCE>

Japan Anti-Tuberculosis Association

Dr. Norio Doi

Dr. Yasuhiro Horita

University of Illinois Chicago

Professor Scott G. Franzblau

Various other research institutes

